Monday morning has greeted the Street on an optimistic note toward large banks, as Goldman Sachs (NYSE: GS) has upped its coverage on the banking sector to "attractive" from "neutral." Goldman went as far as to name some specific banks, including Wells Fargo (NYSE: WFC), which it upped to "buy."

Goldman believes that Wells Fargo's capital position is improving, with it eventually benefiting from its takeover of Wachovia. The brokerage stated that Wells Fargo purchased Wachovia at a "distressed price" and that will help its assets increase 70% from the second quarter of 2007 to the second quarter of 2009.

We're wrapping up the third quarter soon. Earnings will be out in October for most companies, certainly the largest names. They should look very good ... when compared to the third quarter of last year. And the fourth quarter will most likely look even better when comparisons are made.

There's the rub. The percentage increase in earnings will be strong for most companies as many of them wrote down assets, especially in the financials, last year at this time. Mortgages that weren't paying, loans that were way past due, they were losses. Every kind of asset a bank or thrift owned was under scrutiny. Many financials bit the bullet and wrote off large numbers, to get the bad news out of the way. Others nibbled at it, stretching out the pain over several quarters. By now many of those write offs have been taken, and those kinds of losses will be lighter, making earnings much better.

The market seems to want to go up each day as it has relentlessly almost every trading session since April. But yesterday, it had a tiny setback after the FOMC announcement. Today the culprit was housing. The National Association of Realtors said existing home sales declined 2.7% in August. Every economist worth his salt said the number would rise.

Good news on the unemployment front did give the market an early boost this morning. Within an hour, though, bad news on the housing sales front wiped out the gains and moved the major indices into negative territory, where they have remained.

Here were today's unofficial closing numbers:

Dow 9,706.99 -41.56 (-0.43%)
S&P 500 1,050.78 -10.09 (-0.95%)
Nasdaq 2,107.61 -23.81 (-1.12%)

Wells Fargo (NYSE: WFC) announced on Thursday that it will eliminate fees on customer overdrafts of $5 or less and is going to limit overdraft charges to a maximum for four per day.

This move follows similar moves from other large banks, prompting some to ask what took so long. In addition, Wells Fargo customers will be allowed to opt out of automatic overdraft coverage. Doing so would mean that debit card and ATM transactions would not be allowed to go through if your account is overdrawn.

Yesterday my 2009 portfolio closed up 201% for the year. It has been an interesting journey, and while it is rather self congratulatory to discuss it, there are lessons to be learned.

Before I review some of the reasons I was able to do this I want to make it clear that I do not think this can be easily repeated; I look at the portfolio every day thinking this is too good to be true, and we all know what that usually means.

"While I continue to avoid bank stocks and bank ETFs , I very much continue to recommend that you buy and own plenty of nicely high-yielding bank preferreds and bank minibonds for your retirement investing," says Neil George.

In his income-focused Stocks that Pay You, the advisors reviews his favorites among these lesser-known investment vehicles.

"Why invest in banks at all? Because -- as they continue to clean up and bolster their balance sheets -- banks are getting even better credit risks, which means that you'll be even more likely to get paid your high-yield dividends and interest payments.

It was not a good sign. Last night, Cumberland Pharmaceuticals priced its IPO at $17 a share, which was below the $19-$21 range. And, in light of this weakness, the stock is down 9 cents to $16.91 so far in today's trading.

Yet, Cumberland is a fairly solid company. Focused on specialty pharmaceuticals, it has several branded prescription products. The main target areas include: hospital acute care and gastroenterology.

A key differentiator is Cumberland's efficient direct sales model. In all, there are only 66 sales reps. Then again, because of Cumberland's laser focus, it is easier to target the market.